These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
495 related articles for article (PubMed ID: 8528099)
61. Colloidal gold modified with a genetically engineered nitroreductase: toward a novel enzyme delivery system for cancer prodrug therapy. Gwenin VV; Gwenin CD; Kalaji M Langmuir; 2011 Dec; 27(23):14300-7. PubMed ID: 22014024 [TBL] [Abstract][Full Text] [Related]
62. Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial. Martin J; Stribbling SM; Poon GK; Begent RH; Napier M; Sharma SK; Springer CJ Cancer Chemother Pharmacol; 1997; 40(3):189-201. PubMed ID: 9219501 [TBL] [Abstract][Full Text] [Related]
63. Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate. Smith GK; Banks S; Blumenkopf TA; Cory M; Humphreys J; Laethem RM; Miller J; Moxham CP; Mullin R; Ray PH; Walton LM; Wolfe LA J Biol Chem; 1997 Jun; 272(25):15804-16. PubMed ID: 9188478 [TBL] [Abstract][Full Text] [Related]
64. The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT). Knox RJ; Friedlos F; Boland MP Cancer Metastasis Rev; 1993 Jun; 12(2):195-212. PubMed ID: 8375021 [TBL] [Abstract][Full Text] [Related]
65. Prodrugs of anthracyclines for chemotherapy via enzyme-monoclonal antibody conjugates. Gesson JP; Jacquesy JC; Mondon M; Petit P; Renoux B; Andrianomenjanahary S; Dufat-Trinh Van H; Koch M; Michel S; Tillequin F Anticancer Drug Des; 1994 Oct; 9(5):409-23. PubMed ID: 7945725 [TBL] [Abstract][Full Text] [Related]
67. N-(4'-hydroxyphenylacetyl)palytoxin: a palytoxin prodrug that can be activated by a monoclonal antibody-penicillin G amidase conjugate. Bignami GS; Senter PD; Grothaus PG; Fischer KJ; Humphreys T; Wallace PM Cancer Res; 1992 Oct; 52(20):5759-64. PubMed ID: 1356620 [TBL] [Abstract][Full Text] [Related]
68. Advances in prodrug design. Silva AT; Chung MC; Castro LF; Güido RV; Ferreira EI Mini Rev Med Chem; 2005 Oct; 5(10):893-914. PubMed ID: 16250833 [TBL] [Abstract][Full Text] [Related]
69. The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies. Denny WA; Wilson WR J Pharm Pharmacol; 1998 Apr; 50(4):387-94. PubMed ID: 9625483 [TBL] [Abstract][Full Text] [Related]
70. Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds. Springer CJ; Bagshawe KD; Sharma SK; Searle F; Boden JA; Antoniw P; Burke PJ; Rogers GT; Sherwood RF; Melton RG Eur J Cancer; 1991; 27(11):1361-6. PubMed ID: 1835849 [TBL] [Abstract][Full Text] [Related]
71. Tumor-activated prodrugs--a new approach to cancer therapy. Denny WA Cancer Invest; 2004; 22(4):604-19. PubMed ID: 15565818 [TBL] [Abstract][Full Text] [Related]
73. Benzyl ether-linked glucuronide derivative of 10-hydroxycamptothecin designed for selective camptothecin-based anticancer therapy. Leu YL; Chen CS; Wu YJ; Chern JW J Med Chem; 2008 Mar; 51(6):1740-6. PubMed ID: 18318465 [TBL] [Abstract][Full Text] [Related]
74. Enzyme prodrug therapy designed to target L-methioninase to the tumor vasculature. Van Rite BD; Lazrak YA; Pagnon ML; Palwai NR; Neves LF; McFetridge PS; Harrison RG Cancer Lett; 2011 Feb; 301(2):177-84. PubMed ID: 21194833 [TBL] [Abstract][Full Text] [Related]
75. Proteases as activators for cytotoxic prodrugs in antitumor therapy. Weidle UH; Tiefenthaler G; Georges G Cancer Genomics Proteomics; 2014; 11(2):67-79. PubMed ID: 24709544 [TBL] [Abstract][Full Text] [Related]
76. Enzyme/abzyme prodrug activation systems: potential use in clinical oncology. Nishi Y Curr Pharm Des; 2003; 9(26):2113-30. PubMed ID: 14529409 [TBL] [Abstract][Full Text] [Related]
77. A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Francis RJ; Sharma SK; Springer C; Green AJ; Hope-Stone LD; Sena L; Martin J; Adamson KL; Robbins A; Gumbrell L; O'Malley D; Tsiompanou E; Shahbakhti H; Webley S; Hochhauser D; Hilson AJ; Blakey D; Begent RH Br J Cancer; 2002 Sep; 87(6):600-7. PubMed ID: 12237768 [TBL] [Abstract][Full Text] [Related]
78. Photoactivatable prodrugs of highly potent duocarmycin analogues for a selective cancer therapy. Tietze LF; Müller M; Duefert SC; Schmuck K; Schuberth I Chemistry; 2013 Jan; 19(5):1726-31. PubMed ID: 23225610 [TBL] [Abstract][Full Text] [Related]
79. Antibody-enzyme fusion proteins for cancer therapy. Andrady C; Sharma SK; Chester KA Immunotherapy; 2011 Feb; 3(2):193-211. PubMed ID: 21322759 [TBL] [Abstract][Full Text] [Related]
80. Gene directed enzyme prodrug therapy for ovarian cancer: could GDEPT become a promising treatment against ovarian cancer? Nawa A; Tanino T; Luo C; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Nishiyama Y; Kikkawa F Anticancer Agents Med Chem; 2008 Feb; 8(2):232-9. PubMed ID: 18288924 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]